PAVmed raises $45 million, eliminates convertible securities overhang Feb 4, 2026 08:04AM
PAVmed (PAVM) PT Lowered to $17 at Ascendiant Capital Dec 10, 2025 03:53AM
Lucid Diagnostics reports real-world data from 12,000 esophageal tests Dec 9, 2025 08:03AM
PAVmed (PAVM) Misses Q3 EPS by 10c Nov 12, 2025 08:12AM
PAVmed gets 180-day extension from NASDAQ to meet $1 minimum bid price Jul 30, 2025 08:02AM


May 27, 2025 07:31AM Lucid Diagnostics Inc (LUCD) to Join Russell 2000 and Russell 3000 Indexes
May 15, 2025 06:49AM PAVmed (PAVM) Misses Q4 EPS by 16c
Apr 11, 2025 09:26AM Lucid Diagnostics (LUCD) Announces Closing of Public Offering of Common Stock
Apr 10, 2025 06:23AM PAVmed (PAVM) Files $125M Mixed Shelf
Apr 9, 2025 04:01PM Lucid Diagnostics (LUCD) Announces Proposed Public Offering of Common Stock
Mar 17, 2025 07:38AM Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
Mar 13, 2025 07:37AM Lucid Diagnostics Inc (LUCD) Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard Esophageal DNA Test
Mar 5, 2025 04:45PM Lucid Diagnostics Inc (LUCD) Closes $15.3M Direct Offering
Mar 4, 2025 08:25AM Lucid Diagnostics Inc (LUCD) Prices 13.94M Share Offering at $1.10/sh
Feb 27, 2025 08:36AM Lucid Diagnostics Inc (LUCD): Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard in At-Risk Patients without Symptomatic GERD
Feb 25, 2025 08:31AM Lucid Diagnostics (LUCD) Regains Compliance with Nasdaq Minimum Bid Price Requirement
Feb 24, 2025 08:35AM PAVmed (PAVM) and Subsidiary Veris Health Complete Private Placement Financing
Feb 20, 2025 08:31AM Lucid Diagnostics Inc (LUCD) Executes First Concierge Medicine Contract with LEAA Health
Feb 18, 2025 08:31AM PAVmed (PAVM) Regains Compliance with Nasdaq Stockholders' Equity Requirement
Jan 13, 2025 08:00AM Lucid Diagnostics (LUCD) Announces Record Quarterly EsoGuard Test Volume
Dec 23, 2024 08:02AM Lucid Diagnostics Inc (LUCD) Granted Nasdaq Extension to Regain Compliance
Nov 14, 2024 04:33PM PAVmed (PAVM) Misses Q3 EPS by 54c
Nov 5, 2024 08:03AM Lucid Diagnostics (LUCD) Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
Oct 15, 2024 07:51AM Lucid Diagnostics (LUCD) Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
Oct 10, 2024 07:51AM PAVmed (PAVM) Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
Sep 16, 2024 04:30PM PAVmed (PAVM) Announces Efforts to Regain Nasdaq Compliance
Sep 3, 2024 07:52AM Lucid Diagnostics Inc (LUCD) Signs MoU with Front Line Mobile Health
Aug 20, 2024 08:16AM Lucid Diagnostics (LUCD) Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
Aug 13, 2024 08:27AM Lucid Diagnostics Inc (LUCD): American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
Aug 6, 2024 08:15AM Lucid Diagnostics (LUCD) Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Jul 2, 2024 07:55AM Lucid Diagnostics (LUCD) Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Popula